| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
BrainsWay Ltd.$15.06
-0.03 (-0.2%)
D 33Pipeline Score MedTech · Clinical
Market Cap
607.65 M
EPS
0.23
P/E Ratio
67.5 $
Value Trade
2.29 M
-5.03 %
Week
-2.33 %
1 Month
24.48 %
3 Month
110.16 %
6 Month
218.57 %
5 Year
171.1 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
46.42 K
52 Week Range
5.01 - 17.35
% held by Insiders
26.58 %
% held by Institutions
16.42 %
Enterprise Value
555.47 M
Total Shares
40.05 M
Short %
0.42 %
Float Shares
29.42 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for BrainsWay Ltd.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Jun 29, 2026
▲Poster PresentationPresentation
Poster presentation of real-world data on Deep TMS in comorbid PTSD and MDD
comorbid PTSD and MDDsource ↗
Drug Pipeline Intelligence
D33
Pipeline Score $345M
Pipeline ValueValuation Signal
5
Drugs Scored0.6x
rNPV / MCap Top 43%
Micro Cap (rank 520 of 911)
Percentile RankBrainsWay Ltd. faces pipeline headwinds (33/100), with $1.3B risk-adjusted pipeline value, led by Deep Transcranial Magnetic Stimulation in Major Depressive Disorder (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deep Transcranial Magnetic Stimulation Unknown | Major Depressive Disorder | Phase 2 | NCT01409304 | 25% | $614M | COMPLETED | 18 | - | - | Dec 1, 2012 | - | Jan 18, 2013 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SWIFT™ Deep TMS | Major Depressive Disorder | Phase 2 | 2026-06-09 | over 80% of patients remained in remission; percent of patients with severe functional impairment decreased from 85% at baseline to 0% at 12 months; less than 25% of patients had a change in their prescribed medication or another course of TMS within the 12-month period Read More | BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting Read More | |
SWIFT™ Deep TMS | Major Depressive Disorder | Phase 2 | 2026-06-09 | over 80% of patients remained in remission; percent of patients with severe functional impairment decreased from 85% at baseline to 0% at 12 months; less than 25% of patients had a change in their prescribed medication or another course of TMS within the 12-month period Read More | BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting Read More | |
SWIFT™ Deep TMS | Major Depressive Disorder | Phase 2 | 2026-06-09 | over 80% of patients remained in remission; percent of patients with severe functional impairment decreased from 85% at baseline to 0% at 12 months; less than 25% of patients had a change in their prescribed medication or another course of TMS within the 12-month period Read More | BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BWAY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BWAY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BWAYBrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder
BrainsWay Ltd. presented positive data from a large real-world study on Deep TMS for patients with comorbid PTSD and Major Depressive Disorder. The study found that 83.5% of participants experienced significant reductions in PTSD symptoms, with an average decrease of 52%. Additionally, there were notable improvements in depression symptoms, indicating the potential effectiveness of Deep TMS in treating these co-occurring conditions.
Read more →BWAYBrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BrainsWay Ltd. has announced an expansion in coverage for its SWIFT Accelerated Deep TMS protocol, now reaching over 57 million covered lives across the U.S. This includes a new policy in South Carolina covering 2 million members. The company emphasizes the importance of this milestone in improving patient access to Deep TMS therapies for conditions like major depressive disorder and obsessive-compulsive disorder.
Read more →BWAYBrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting
BrainsWay presented new 12-month durability data for its SWIFT™ Deep TMS protocol at the Clinical TMS Society Meeting. The study showed that over 80% of patients remained in remission, with significant improvements in functional impairment. This research highlights the long-term benefits of the SWIFT™ protocol compared to traditional methods, reinforcing its efficacy in treating Major Depressive Disorder.
Read more →BWAYBrainsWay Announces Minority-Stake Investment in Hopemark Health
BrainsWay Ltd. has announced a strategic investment of $1.5 million in Hopemark Health, with potential for an additional $1.5 million. This partnership aims to enhance access to advanced mental health treatments and improve patient outcomes. Both companies express optimism about the collaboration, which aligns with BrainsWay's goal of expanding its influence in interventional psychiatry.
Read more →BWAYBrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights
BrainsWay Ltd. reported a strong financial performance for Q1 2026, with revenue increasing by 35% to $15.5 million and net income more than doubling to $2.3 million. The company also highlighted a significant demand for its Deep TMS systems, shipping a record 117 units. Additionally, BrainsWay reiterated its full-year financial guidance, projecting revenue between $66 million and $68 million.
Read more →BWAYFrom an innovative technology to a fast - growing ARR company Investor Deck May 2026 Nasdaq/TASE: BWAY Investor Deck | May 2026
BrainsWay presented their investor deck for May 2026, highlighting its continuous growth and profitability. The company reported a 35% revenue increase to $15.5 million in Q1 2026 and aims for total revenue of $66 million to $68 million for the year. With expanding treatment center installations and reinforcing its financial standing, BrainsWay is progressing through various clinical trials. However, the company remains cautious about potential uncertainties that could impact future performance.
Read more →BWAYFrom an innovative technology to a fast - growing ARR company Investor Deck March 2026 Nasdaq/TASE: BWAY Investor Deck | March 2026
BrainsWay has reported strong financial results for Q4 2025, demonstrating a 27% year-over-year revenue growth and a net income increase of 161%. The company received FDA clearance for new treatment protocols, further expanding its market capabilities. With a solid installed base of over 1,700 treatment centers, BrainsWay is positioned for continued growth, supported by a 93% customer retention rate. Additionally, the company emphasizes its transition to a high-margin annual recurring revenue model, promising enhanced financial stability going forward.
Read more →BWAYAdvanced Noninvasive Neurostimulation Treatments for Mental Health Disorders Investor Deck November 2025 Nasdaq/TASE: BWAY Investor Deck | November 2025
BrainsWay, traded as BWAY, presented its Investor Deck for November 2025, highlighting substantial growth in its neurostimulation treatments for mental health disorders. The company reported a 29% year-over-year revenue increase, with an adjusted EBITDA growth of 81% and a net profit rise of 137%, driven by a robust multi-year lease structure and recent FDA clearance for new treatment protocols. Additionally, BrainsWay has secured a $2.5M NIH grant for research on alcohol use disorder, positioning itself strongly in the mental health market. Future growth strategies include expanding partnerships and introducing its technologies to new clinical settings.
Read more →BWAYThe Power of PX: Why Patient Experience Is the Most Overlooked Driver of Growth in TMS
The article emphasizes the importance of Patient Experience (PX) in driving growth for TMS clinics. It highlights how enhancing PX can lead to increased patient trust, higher conversion rates, and improved revenue without additional advertising costs. Real-world examples illustrate successful implementations of PX strategies, and Rise4 offers resources for clinics to assess and improve their patient experience.
Read more →BWAYA New Era in Brain Disorder Treatment Corporate Presentation Nasdaq/TASE: BWAY August 2025
BrainsWay (BWAY) presented its corporate strategy and financial outlook, highlighting its leadership in noninvasive neurostimulation treatments for mental health disorders. The company reported a revenue increase of 26% year-over-year, reaching $12.6 million in Q2 2025, with raised guidance for the full year. A significant partnership with Valor Equity Partners has secured $20 million in funding, enhancing growth opportunities. BrainsWay's innovative business model, focusing on recurring revenue from long-term contracts, positions it for continued financial stability and expansion in the mental health sector.
Read more →BWAYHow Deep TMS Targets Brain Networks for Mood Regulation
The article discusses how BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) targets interconnected brain networks to improve mood regulation. It highlights the importance of the Central Executive Network, Default Mode Network, and Salience Network in mental health conditions. The patented H-Coil design of Deep TMS allows for deeper and broader stimulation, potentially leading to more effective treatments for disorders like depression and OCD.
Read more →BWAYSafety and efficacy of Deep TMS for adolescent depression based on large real-world data analysis
A study evaluated the safety and efficacy of Deep TMS for adolescents with major depressive disorder, involving 217 participants across 36 clinical sites. Results showed that 52% achieved a significant clinical response and 28% reached remission after about 29 treatment sessions. The treatment was well-tolerated, with mild side effects and no serious adverse events, indicating its viability for youth.
Read more →BWAYBrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles
BrainsWay will showcase its Deep TMS technology at the 2025 American Psychiatric Association Annual Meeting in Los Angeles. The company will conduct live demonstrations at its booth and participate in a Master Course focused on advanced psychiatric treatments. Key presentations will be made by Dr. Richard Bermudes and Dr. Colleen Hanlon, emphasizing BrainsWay's commitment to mental health innovation.
Read more →BWAY15 Effective Ways to Cope with Seasonal Depression and Brighten Your Winter Days
The article discusses Seasonal Affective Disorder (SAD), a condition affecting about 5% of U.S. adults, particularly during winter months. It outlines effective coping strategies, including lifestyle changes such as embracing natural light and regular exercise, as well as advanced treatments like Deep TMS. The importance of social connections and mindfulness practices is also emphasized for managing symptoms.
Read more →BWAYUnderstanding Depression in Older Adults: Challenges, Stigma, and Treatment with BrainsWay Deep TMS
The article discusses the challenges of diagnosing and treating late-life depression, emphasizing the barriers faced by older adults, such as stigma and overlapping health conditions. It highlights the importance of accurate diagnosis and the role of providers in facilitating treatment options like BrainsWay Deep TMS, which has shown promising efficacy in older patients. The article advocates for empathetic communication and the use of non-pharmacological approaches to improve mental health outcomes.
Read more →BWAYNational Depression Awareness Month 2024: A Spotlight on Treatments
National Depression Awareness Month in October aims to highlight depression and mental health issues, encouraging education and reducing stigma. The article discusses the complexities of treating depression, especially when it coexists with conditions like OCD. It emphasizes the importance of personalized treatment plans and highlights the benefits of BrainsWay Deep TMS as a noninvasive option for treatment-resistant depression.
Read more →BWAYEfficacy and Safety of Deep Transcranial Magnetic Stimulation Versus High-Frequency Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder: A Systematic Review
This systematic review compares the efficacy and safety of deep transcranial magnetic stimulation (dTMS) and high-frequency repetitive transcranial magnetic stimulation (HF-rTMS) for major depressive disorder (MDD). The findings indicate that dTMS has a higher overall antidepressant response rate (60.0%) compared to HF-rTMS (41.7%). While dTMS is associated with more muscle-related side effects, both treatments maintain favorable safety profiles. The review calls for more rigorous studies to validate these results.
Read more →BWAYThe Role of Transcranial Magnetic Stimulation Therapy in Managing Anxiety Disorders
Transcranial Magnetic Stimulation (TMS) therapy is emerging as a promising treatment for anxiety disorders, particularly for those who are treatment-resistant. BrainsWay's Deep TMS utilizes advanced technology to stimulate deeper brain structures, enhancing emotional regulation. Clinical studies show it is effective for anxious depression and OCD, with many patients reporting improvements within weeks. While generally safe, mild side effects may occur.
Read more →BWAYUnderstanding the OCD Cycle
The article discusses the OCD cycle, which includes obsession, anxiety, compulsion, and temporary relief. It highlights the debilitating nature of obsessive-compulsive disorder and the challenges faced by patients. Advances such as BrainsWay Deep TMS provide new treatment options, showing promise for those with treatment-resistant OCD. The article emphasizes the importance of therapy and medication in managing the disorder.
Read more →BWAYTreatment Options for Late-Life Depression
Late-life depression is increasingly recognized as a significant public health concern affecting the elderly. Various treatment options, including antidepressants, psychotherapy, and neurostimulation, are available, but they come with challenges such as non-response rates and accessibility issues. Additionally, lifestyle interventions like exercise and social engagement are important but face barriers. A tailored approach is essential for effective management.
Read more →BWAYUnderstanding Late-Life Depression: Challenges and Potential Solutions
The article discusses the challenges and potential solutions for treating late-life depression, particularly Major Depressive Disorder (MDD) in elderly patients. It highlights the increasing prevalence of depression among older adults and the limitations of first-generation therapies. Emerging treatments like Deep Transcranial Magnetic Stimulation (Deep TMS) show promise in improving outcomes for this demographic. The article emphasizes the need for innovative approaches to address the unique needs of elderly patients suffering from depression.
Read more →BWAYThe Clinical Efficacy of Accelerated Deep Repetitive Transcranial Magnetic Stimulation in Depression and Obsessive-Compulsive Disorder: Multi-centric Real-World Observational Data
The study evaluates the efficacy of an accelerated TMS protocol for treating depression and OCD. Results show a 60.86% response rate in depression and 62.76% in OCD, with significant score reductions. The findings suggest that this accelerated approach is effective without serious side effects, comparable to standard treatment protocols.
Read more →BWAYDeep TMS for adolescents with treatment-resistant depression: A preliminary dose-finding study exploring safety and clinical effectiveness
A pilot study evaluated the safety and efficacy of deep transcranial magnetic stimulation (dTMS) in adolescents with treatment-resistant depression (TRD). Out of 15 participants, 14 completed the treatment, showing significant improvements in depression symptoms. While one participant experienced a convulsive syncope, the overall side effects were mild, indicating dTMS may be a viable option for adolescent TRD.
Read more →BWAYEfficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial
A study on high-dose deep rTMS for late-life depression found significant efficacy, with a remission rate of 40% compared to 14.8% in the sham group. The treatment was safe and well tolerated, with no serious adverse events. However, pain was reported more frequently in the active treatment group, highlighting a potential drawback.
Read more →BWAYNever Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression
A phase IV study evaluated the safety and efficacy of Deep TMS in treating late-life major depressive disorder (MDD) in 247 patients aged 60-91. After 30 sessions, response rates reached 79.4% and remission rates were 60.3%. The treatment was well tolerated, with no serious adverse events reported, indicating its effectiveness for older adults with treatment-resistant depression.
Read more →BWAYSynergistic use of deep TMS therapy with IV ketamine infusions for major depressive disorder: a pilot study
A pilot study investigated the synergistic use of deep TMS therapy and IV ketamine infusions in patients with treatment-resistant major depressive disorder (MDD). Results showed significant reductions in depressive symptoms for both treatment groups, with high response rates. However, the addition of ketamine did not provide a significant advantage over TMS alone. Further research is recommended to explore these findings.
Read more →BWAYTreatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials
This network meta-analysis evaluated treatment options for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder (OCD). It included 55 randomized controlled trials and identified deep TMS, ondansetron, CBT-TA, and aripiprazole as effective first-line interventions. While deep TMS emerged as the most effective, caution is advised due to variability in study sizes and results.
Read more →BWAYReal-world data of non-invasive stimulation of the human insula-prefrontal cortices using deep TMS to treat anxiety for occupational stress and generalized anxiety disorder
The study investigates the effectiveness of Deep Transcranial Magnetic Stimulation (TMS) in reducing anxiety symptoms related to occupational stress and generalized anxiety disorder (GAD). Results indicate significant improvements in anxiety levels among participants, suggesting the efficacy of this treatment in real-world settings. Further research is needed to validate these findings.
Read more →BWAYDepressive symptoms during deep transcranial magnetic stimulation or sham treatment for obsessive-compulsive disorder
The study investigates the relationship between obsessive-compulsive disorder (OCD) and depressive symptoms in patients undergoing deep transcranial magnetic stimulation (dTMS). Results indicate that while both symptom types improved significantly, there was no predictive relationship between them. This suggests that depression symptoms may decrease with dTMS treatment for OCD, but monitoring is essential.
Read more →BWAY▲ +6.1%on this news· ran to +22% by day 3
Durability of Deep Transcranial Magnetic Stimulation for Veterans with Treatment-Resistant Depression with Comorbid Suicide Risk and PTSD Symptoms
The study assesses the effectiveness of deep transcranial magnetic stimulation (dTMS) in veterans with treatment-resistant depression (TRD), suicide risk, and PTSD symptoms. After 30 treatment sessions, significant reductions in depression, PTSD, and suicidal ideation were observed at the six-month follow-up. The findings highlight the potential of dTMS as a durable treatment option for this population.
Read more →BWAYAre There Stages of Depression?
The article clarifies that depression does not occur in stages like grief, despite common misconceptions. It outlines the symptoms of depression and emphasizes its treatability through various methods, including psychotherapy, medication, and advanced treatments like Deep TMS. The importance of seeking help and understanding depression is highlighted.
Read more →BWAY▲ +12.9%on this news· ran to +26% by day 3
Comparison of the analgesic effects of “superficial” and “deep” repetitive transcranial magnetic stimulation in patients with central neuropathic pain: a randomized sham-controlled multicenter international crossover study
A study compared the analgesic effects of superficial and deep repetitive transcranial magnetic stimulation (rTMS) in patients with central neuropathic pain. Fifty-nine patients participated in a randomized, sham-controlled crossover design. Results showed both stimulation types provided significant analgesic effects, with superficial stimulation acting faster and deep stimulation having longer-lasting effects. The findings suggest distinct mechanisms of action for each type.
Read more →BWAY▲ +13.1%on this news· ran to +27% by day 3shared move
Deep magnetic stimulation targeting the medial prefrontal and anterior cingulate cortices for methamphetamine use disorder: a randomised, double-blind, sham-controlled study
The study demonstrates that chronic rTMS targeting the medial prefrontal cortex and anterior cingulate cortex significantly reduces cravings in individuals with methamphetamine use disorder. It highlights the importance of these brain regions in craving generation and suggests that rTMS could be an effective intervention for addiction treatment. Additionally, the study notes changes in neural oscillation patterns, particularly in the MPFC.
Read more →BWAY▲ +13.6%on this news· ran to +27% by day 3shared move
Deep Transcranial Magnetic Stimulation in combination with symptoms provocation: An effective treatment in patients with treatment-resistant Body Dysmorphic Disorder?
This article discusses a case series involving three patients with treatment-resistant Body Dysmorphic Disorder (BDD) who were treated with deep Transcranial Magnetic Stimulation (dTMS) combined with symptom provocation. The treatment resulted in a reduction of symptoms for all patients. These findings highlight the potential of dTMS as a viable option for BDD, though further research is needed.
Read more →BWAY▲ +12.7%on this news· ran to +26% by day 3shared move
Past, present, and future of deep transcranial magnetic stimulation: A review in psychiatric and neurological disorders
The article reviews deep transcranial magnetic stimulation (dTMS), highlighting its innovative approach to treating psychiatric and neurological disorders. It discusses the advantages of the H-coil technology, which allows for stimulation of deeper brain regions and broader coverage. Clinical advancements in dTMS are noted for conditions such as Parkinson's disease, Alzheimer's disease, and various mental health issues.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Accelerated deep transcranial magnetic stimulation using iTBS protocol for refractory obsessive-compulsive disorder
The article discusses two cases showcasing the safety and potential effectiveness of an accelerated deep transcranial magnetic stimulation (dTMS) protocol for treating refractory obsessive-compulsive disorder (OCD). This new approach may offer quicker clinical improvements compared to conventional methods. However, the need for additional sessions to ensure sustained responses remains uncertain, highlighting the necessity for more systematic studies.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Behavioral and Functional Brain Activity Alterations Induced by TMS Coils with Different Spatial Distributions
This study explores the impact of different transcranial magnetic stimulation (TMS) coils on behavioral and brain activity changes. By using the Figure-8 coil and H-Coil, researchers found that stimulation of the right lateral prefrontal cortex (LPFC) influenced reward-related behavior and brain activation. The results suggest that the right LPFC plays a significant role in these processes, indicating the potential for TMS coils with varied spatial profiles to enhance our understanding of brain-behavior relationships.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Deep Transcranial Magnetic Stimulation as a Potential Approach for Digital Pain Management in Patients with Psychotic Disorder
The article discusses the potential of Deep Transcranial Magnetic Stimulation (dTMS) as a novel approach for digital pain management in patients with psychotic disorders. It highlights recent research findings that suggest dTMS may offer effective treatment options for individuals facing challenges with traditional therapies. The implications for future clinical practices are also considered.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Safety and efficacy of H7 deep transcranial magnetic stimulation in adolescent obsessive‐compulsive disorder: A case report
The article reports on the first use of deep transcranial magnetic stimulation (dTMS) with an H7 coil in an adolescent suffering from treatment-resistant obsessive-compulsive disorder (OCD). After 10 sessions, the patient showed significant clinical improvement, which was well tolerated. The benefits were maintained during a one-month follow-up, indicating the treatment's safety and efficacy.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Clinical Efficacy of Deep Transcranial Magnetic Stimulation in Psychiatric and Cognitive Disorders: Protocol for a Systematic Review
This article outlines a protocol for a systematic review on the clinical efficacy of deep transcranial magnetic stimulation (dTMS) in treating psychiatric and cognitive disorders. The review aims to compare active dTMS with sham treatments and explore subgroup differences. Initial findings indicate a total of 22 eligible articles for inclusion, with ongoing data extraction and quality assessment planned.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Brain activation alterations with adjunctive deep transcranial magnetic stimulation in obsessive-compulsive disorder: an fMRI study
The study investigates the effectiveness of adjunctive deep transcranial magnetic stimulation (dTMS) in treating obsessive-compulsive disorder (OCD). Fifteen patients underwent ten sessions of dTMS, resulting in significant improvements in OCD, anxiety, and depressive symptoms. fMRI results showed decreased activation in the left caudate nucleus during cognitive tasks post-treatment, suggesting dTMS may effectively modulate brain activity associated with OCD.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Efficacy of insula deep repetitive transcranial magnetic stimulation combined with varenicline for smoking cessation: A randomized, double-blind, sham controlled trial
This study evaluated the efficacy of insula-targeted repetitive transcranial magnetic stimulation (rTMS) combined with varenicline for smoking cessation. In a randomized trial with 42 participants, the active rTMS group achieved a higher abstinence rate of 82.4% compared to 30.7% in the sham group. Secondary outcomes did not show significant differences, but the results indicate potential benefits of this combined approach.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Deep transcranial magnetic stimulation alters resting-state neurophysiological traits in major depressive disorder
The study investigates the effects of Deep TMS on patients with major depressive disorder (MDD). It found that after 36 treatment sessions, there was a notable decrease in slow-frequency brain activity in the prefrontal cortex. Additionally, baseline QEEG measures accurately predicted treatment responses, suggesting that Deep TMS could be a valuable tool in treating MDD.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
The effect of deep repetitive transcranial magnetic stimulation with an H1 coil on hopelessness in patients with major depressive disorder: A randomized controlled trial
This study evaluated the effectiveness of high-frequency repetitive transcranial magnetic stimulation (rTMS) using an H1 coil in reducing hopelessness among patients with major depressive disorder (MDD). Conducted in Croatia, the randomized controlled trial involved 103 participants, revealing a significant reduction in Beck Hopelessness Scale scores in the rTMS group compared to the control group. The findings suggest rTMS could be a beneficial treatment for hopelessness in MDD.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Real world efficacy and safety of various accelerated deep TMS protocols for major depression
A Phase IV study evaluated the safety and efficacy of various accelerated Deep TMS protocols for major depressive disorder. The study involved 111 patients and found an 80.2% response rate and a 50.5% remission rate within the first month. No significant differences were noted between the different protocols, and the treatment was well-tolerated with no serious adverse events reported.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Moderators of the Response to Deep TMS for Smoking Addiction
The FDA has cleared Deep TMS as a short-term treatment for smoking cessation. A study analyzed data from 262 participants to identify factors influencing treatment efficacy. Results showed younger, more educated Caucasian individuals had significantly higher quit rates. In contrast, older participants with extensive smoking histories may need longer or combined treatments.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Revisiting the Rotational Field TMS Method for Neurostimulation
The article discusses rotational field TMS (rfTMS), a method designed to enhance the efficacy of transcranial magnetic stimulation for treating major depressive disorder and other neuropsychiatric conditions. Unlike conventional TMS, rfTMS activates a larger number of neurons, potentially reducing variability in treatment outcomes. However, further clinical trials are necessary to validate its effectiveness.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder
The article discusses the FDA clearance of the H7 Coil for treating treatment-refractory Obsessive-Compulsive Disorder (OCD), supported by results from two randomized controlled trials (RCTs). Additionally, the D-B80 and iron-core figure-8 coils received 510K clearance, highlighting advancements in transcranial magnetic stimulation technology. The physical properties of these coils differ, potentially affecting their functional applications.
Read more →BWAY▲ +10.6%on this news· ran to +24% by day 3shared move
Adverse childhood experiences and repetitive transcranial magnetic stimulation outcomes for depression
The study investigates the impact of adverse childhood experiences (ACEs) on depression treatment outcomes in patients receiving repetitive transcranial magnetic stimulation (rTMS). A retrospective analysis of 99 patients showed that while ACEs may lead to a quicker reduction in depression symptoms initially, they did not significantly affect overall treatment outcomes. The findings suggest that high ACE scores should not deter the use of rTMS for depression.
Read more →BWAYTranscranial Magnetic Stimulation as a Tool to Promote Smoking Cessation and Decrease Drug and Alcohol Use
Repetitive transcranial magnetic stimulation (rTMS) has been cleared by the FDA for smoking cessation and is being investigated for other substance use disorders. The article reviews the neural networks involved in addiction and discusses the efficacy of rTMS in targeting specific brain circuits. It highlights significant studies and notes the need for further research to explore the mechanisms of rTMS.
Read more →BWAY▲ +9%on this newsshared move
Deep TMS: A comprehensive summary of adverse events from five multicenter trials
The article summarizes the adverse event profile of Deep TMS treatments using H1, H4, and H7 Coils from five multicenter randomized controlled trials involving 884 patients. It highlights the frequency and types of adverse events, noting that most were transient and resolved within days. This analysis represents a significant contribution to understanding the safety of Deep TMS.
Read more →BWAYCan We Deliver TMS to Patients With Implanted Devices? A Practical Summary of the Recent Safety Recommendations
The article discusses safety recommendations for delivering Transcranial Magnetic Stimulation (TMS) to patients with implanted devices. It highlights that many misconceptions about TMS and metallic implants are addressed, indicating that TMS is generally safe for such patients. However, it notes that overly conservative FDA guidelines may restrict TMS access, particularly for those with deep brain stimulators.
Read more →BWAYHartum Street, Bynet Building, 3rd Floor
19 Hartum Street, Bynet Building, 3rd Floor Har HaHotzvim, Jerusalem 9777518 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 22, 2021 The Annual General Meeting of Shareholders of BrainsWay Ltd. (the "Company"), will be held at the offices of the Comp
Read more →BWAYBRAINSWAY LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2020 U.S. DOLLARS IN THOUSANDS UNAUDITED INDEX Page Condensed Interim Consolidated Statements of Financial Position 2 Condensed Inter
INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF SEPTEMBER 30, 2020 DOLLARS IN THOUSANDS Page Condensed Interim Consolidated Statements of Financial Position 2 Condensed Interim Consolidated Statements of Comprehensive Loss 3 Condensed Interim Consolidated Statements of Changes i
Read more →BWAYBrainsway Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares JERUSALEM, ISRAEL
Brainsway Ltd. Announces Pricing of Initial Public Offering of 2.5 Million American Depositary Shares JERUSALEM, ISRAEL, April 16, 2019 Brainsway Ltd. (NASDAQ: BWAY and TASE: BRIN) ( Brainsway ) today announced that it has priced its initial public offering of 2,500,000 America
Read more →Competitive Position
How BWAY ranks across every disease it competes inCompetitive Position is a premium feature
See how BWAY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial